	e: <u>25 August, 2021</u> r Name: <u>Hitomi Nogav</u>	va				
	Manuscript Title: <u>Diagnostic usefulness of bronchoscopy for peripheral pulmonary lesions in</u>					
	patients with idiopathic pulmonary fibrosis					
Mar	Manuscript number (if known): <u>JTD-21-1067</u>					
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u> .  The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your						
to the of a limit	manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,					
the	time frame for disclosui	re is the past 36 month	S.			
	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)					
	Tin	ne frame: Since the initia	l planning of the work			
1	All support for the	None				
	present manuscript (e.g., funding, provision					
	of study materials, medical writing, article					
	processing charges,					

etc.)

item.

No time limit for this

I	I		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
_			
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria	None	
	for lectures, presentations, speakers		
	bureaus, manuscript writing or educational		
	events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued	None	
	or pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory		
	Board		
10	Leadership or fiduciary	None	
	role in other board,		
	society, committee or		

	advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-	None	
	financial interests		

Hitomi Nogawa has no conflicts of interest directly relevant to the content of this article.				

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Your Name: Yuji Matsumoto  Manuscript Title: Diagnostic usefulness of bronchessony for peripheral nulmonary lesions i					
Manuscript Title: Diagnostic usofulness of branchessony for norinboral nulmanary lesions i					
Manuscript Title: <u>Diagnostic usefulness of bronchoscopy for peripheral pulmonary lesions in</u>					
patients with idiopathic pulmonary fibrosis					
Manuscript number (if known): <u>JTD-21-1067</u>					
In the interest of transparency, we ask you to disclose all relationships/activities/interests					
listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-					
for-profit third					
parties whose interests may be affected by the content of the manuscript. Disclosure					
represents a commitment					
to transparency and does not necessarily indicate a bias. If you are in doubt about whether the list a relationship/activity/interest, it is preferable that you do so.					
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u> .					
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if you					
manuscript pertains					
to the epidemiology of hypertension, you should declare all relationships with manufacturer of antihypertensive medication, even if that medication is not mentioned in the manuscript.					
of antihypertensive medication, even if that medication is not mentioned in the manuscript.					
In item #1 below, report all support for the work reported in this manuscript without time					
limit. For all other items,					
limit. For all other items,					
limit. For all other items,					
limit. For all other items,					
limit. For all other items, the time frame for disclosure is the past 36 months.					
limit. For all other items, the time frame for disclosure is the past 36 months.  Name all entities with whom you have this relationship or (e.g., if payments were made to you or to you institution)					
limit. For all other items, the time frame for disclosure is the past 36 months.  Name all entities with whom you have this relationship or indicate none (add  Specifications/Comments (e.g., if payments were made to you or to you institution)					
limit. For all other items, the time frame for disclosure is the past 36 months.  Name all entities with whom you have this relationship or (e.g., if payments were made to you or to you institution)					
limit. For all other items, the time frame for disclosure is the past 36 months.  Name all entities with whom you have this relationship or indicate none (add  Specifications/Comments (e.g., if payments were made to you or to you institution)					
limit. For all other items, the time frame for disclosure is the past 36 months.  Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial planning of the work					
limit. For all other items, the time frame for disclosure is the past 36 months.  Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial planning of the work  1 All support for the None					
limit. For all other items, the time frame for disclosure is the past 36 months.    Name all entities with whom you have this relationship or indicate none (add rows as needed)     Time frame: Since the initial planning of the work     All support for the present manuscript   None					
limit. For all other items, the time frame for disclosure is the past 36 months.  Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial planning of the work  All support for the present manuscript (e.g., funding, provision					
limit. For all other items, the time frame for disclosure is the past 36 months.    Name all entities with whom you have this relationship or indicate none (add rows as needed)     Time frame: Since the initial planning of the work     All support for the present manuscript   None					
limit. For all other items, the time frame for disclosure is the past 36 months.  Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial planning of the work  All support for the present manuscript (e.g., funding, provision of study materials,					
limit. For all other items, the time frame for disclosure is the past 36 months.    Name all entities with whom you have this relationship or indicate none (add rows as needed)					
limit. For all other items, the time frame for disclosure is the past 36 months.    Name all entities with whom you have this relationship or indicate none (add rows as needed)     Time frame: Since the initial planning of the work					

I	I		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	National Cancer Center Research and Development Fund Grant-in-Aid for Scientific Research on Innovative Areas Hitachi, Ltd.	
_			
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria	Olympus	
	for lectures, presentations, speakers bureaus, manuscript	Erbe Elektromedizin GmbH	
	writing or educational events	AMCO INC.	
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued	None	
	or pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory		
	Board		

10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non-financial interests	None

Yuji Matsumoto reports grants from National Cancer Center Research and Development Fund, grants from Grant-in-
Aid for Scientific Research on Innovative Areas, grants from Hitachi, Ltd., personal fees from Olympus, personal fees
from Erbe Elektromedizin GmbH, personal fees from AMCO INC., outside the submitted work.

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 28 August, 2021

Your Name: Midori Tanaka						
Manuscript Title: <u>Diagnostic usefulness of bronchoscopy for peripheral pulmonary lesions in</u>						
patients with idiopathic pulmonary fibrosis						
M	Manuscript number (if known):JTD-21-1067					
lis fo pa re to	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.					
		following questions appose current manuscript o		tionships/activities/interests as they relate		
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.						
of			· •	<del>-</del>		
In lir	f an n ite mit	ntihypertensive medica	tion, even if that medic	cation is not mentioned in the manuscript.		
In lir	f an n ite mit	ntihypertensive medica em #1 below, report all t. For all other items,	tion, even if that medic	cation is not mentioned in the manuscript.		
In lir	f an n ite mit	ntihypertensive medica em #1 below, report all t. For all other items, time frame for disclosui	support for the work re is the past 36 month  Name all entities with whom you have this relationship or indicate none (add	cation is not mentioned in the manuscript.  eported in this manuscript without time  is.  Specifications/Comments (e.g., if payments were made to you or to your institution)		
In lir th	f an ito	ntihypertensive medica em #1 below, report all t. For all other items, time frame for disclosur	support for the work re is the past 36 month.  Name all entities with whom you have this relationship or indicate none (add rows as needed).	cation is not mentioned in the manuscript.  eported in this manuscript without time  is.  Specifications/Comments (e.g., if payments were made to you or to your institution)		
In lir	f an ito	ntihypertensive medica em #1 below, report all t. For all other items, time frame for disclosur	support for the work re is the past 36 month.  Name all entities with whom you have this relationship or indicate none (add rows as needed)	cation is not mentioned in the manuscript.  eported in this manuscript without time  is.  Specifications/Comments (e.g., if payments were made to you or to your institution)		
In lir th	f an ito	ntihypertensive medica em #1 below, report all t. For all other items, time frame for disclosur  Tir  All support for the present manuscript	support for the work re is the past 36 month.  Name all entities with whom you have this relationship or indicate none (add rows as needed).	cation is not mentioned in the manuscript.  eported in this manuscript without time  is.  Specifications/Comments (e.g., if payments were made to you or to your institution)		
In lir th	f an ito	ntihypertensive medica em #1 below, report all t. For all other items, time frame for disclosur	support for the work re is the past 36 month.  Name all entities with whom you have this relationship or indicate none (add rows as needed).	cation is not mentioned in the manuscript.  eported in this manuscript without time  is.  Specifications/Comments (e.g., if payments were made to you or to your institution)		
In lir th	f an ito	Tir All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	support for the work re is the past 36 month.  Name all entities with whom you have this relationship or indicate none (add rows as needed).	cation is not mentioned in the manuscript.  eported in this manuscript without time  is.  Specifications/Comments (e.g., if payments were made to you or to your institution)		
In lir th	f an ito	Tir  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	support for the work re is the past 36 month.  Name all entities with whom you have this relationship or indicate none (add rows as needed).	cation is not mentioned in the manuscript.  eported in this manuscript without time  is.  Specifications/Comments (e.g., if payments were made to you or to your institution)		
In lir th	f an ito	Tir  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	support for the work re is the past 36 month.  Name all entities with whom you have this relationship or indicate none (add rows as needed).	cation is not mentioned in the manuscript.  eported in this manuscript without time  is.  Specifications/Comments (e.g., if payments were made to you or to your institution)		
In lir th	f an ito	Tir  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	support for the work re is the past 36 month.  Name all entities with whom you have this relationship or indicate none (add rows as needed).	cation is not mentioned in the manuscript.  eported in this manuscript without time  is.  Specifications/Comments (e.g., if payments were made to you or to your institution)		

		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or	None	

	advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-	None	
	financial interests		

Midori Tanaka has no conflicts of interest directly relevant to the content of this article.				

Please place an "X" next to the following statement to indicate your agreement:

\_X \_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Manuscript Title: <u>Diagnostic usefulness of bronchoscopy for peripheral pulmonary lesions in</u>

Date: 2 September, 2021
Your Name: Takaaki Tsuchida

-	ents with idiopathic pul nuscript number (if knov		<u></u>				
liste relate for-parte represent to trelist a	d below that are ted to the content of your or of third ies whose interests may esents a commitment ansparency and does not relationship/activity/in	ur manuscript. "Relate y be affected by the cor ot necessarily indicate nterest, it is preferable	lose all relationships/activities/interests  d" means any relation with for-profit or not- ntent of the manuscript. Disclosure  a bias. If you are in doubt about whether to that you do so.  tionships/activities/interests as they relate				
The man to th of an In ite	author's relationships/a suscript pertains ne epidemiology of hypo ntihypertensive medica	ertension, you should on the standard of the standard of the support for the work results.	uld be defined broadly. For example, if your declare all relationships with manufacturers cation is not mentioned in the manuscript. eported in this manuscript without time s.				
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
	Time frame: Since the initial planning of the work						
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None					

Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	Japan Agency for Medical Research and Development	Grant for Medical Research	
		Foundation for Promotion Cancer Research	Grant for Medical Research	
3	Royalties or licenses	None		
4	Consulting fees	None		
_	Day was and an harman wards	Nime on Manding!	Daniel Canada di an Davier Canada di an	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Nippon Medical School Foundation	Degree Examination Review Committee	
6	Payment for expert testimony	None		
_	Command for other direct	None		
7	Support for attending meetings and/or travel	None		
8	Patents planned, issued or pending	None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	Hamamatsu University School of Medicine	Safety Monitoring Board	

10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

Takaaki Tsuchida reports grants from Japan Agency for Medical Research and Development, grants from Foundation for Promotion Cancer Research, personal fees from Nippon Medical School Foundation, personal fees from Hamamatsu University School of Medicine, outside the submitted work.

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.